June 2026 Lab Notes: The Truth Behind Statins, GLP-1s, and Aspirin

For decades, concerns have swirled around statins and their potential to increase diabetes risk. Now, a major meta-analysis of large-scale, blinded trials puts the data into sharp focus. While statin therapy does cause a small but consistent rise in HbA1c—0.06% with low- or moderate-intensity regimens and 0.08% with high-intensity ones—this shift primarily affects individuals already near the diabetes threshold. In fact, about 62% of new-onset diabetes cases linked to statins occur in people whose baseline glucose levels are in the top 25%.

The relative increase in diabetes diagnoses is 10% for moderate regimens and jumps to 36% for high-intensity statins. But the absolute annual risk increase is just 0.12% for moderate and 1.27% for high-intensity therapy. Crucially, this small metabolic cost is far outweighed by the substantial reduction in cardiovascular events, especially in high-risk patients.

The takeaway? Statins remain a cornerstone of heart disease prevention. The slight glucose shift isn’t a reason to avoid them—but it does suggest we should monitor blood sugar more closely in prediabetic patients on high-dose statins.

The metabolic magic of GLP-1 receptor agonists like liraglutide isn’t just about shedding pounds. A high-scoring study reveals that these drugs improve insulin sensitivity and glucose control within just two weeks—long before significant weight loss occurs. In people with obesity and prediabetes, liraglutide rapidly lowers fasting and postprandial glucose, independent of calorie restriction or endogenous GLP-1 boosts from drugs like sitagliptin.

Even more compelling: when researchers blocked the GLP-1 receptor with exendin(9-39), the metabolic benefits vanished. This confirms that the improvements are specifically tied to GLP-1 receptor activation, not just secondary effects of weight loss or appetite suppression.

This finding reshapes how we view these drugs—not just as weight-loss tools, but as direct modulators of metabolic health. For those with prediabetes, that early glucose control could be a game-changer.

For years, many healthy older adults took daily aspirin hoping to stave off heart attacks and strokes. But new evidence from a large trial shows that 100 mg of enteric-coated aspirin daily does not reduce major cardiovascular events in adults over 70. Over nearly five years, the rate of heart attacks, strokes, and fatal coronary events was nearly identical between aspirin and placebo groups.

Even more concerning: the bleeding risk doesn’t fade over time. Instead, it increases linearly, with no sign of the body adapting. Major hemorrhages accumulate steadily, meaning the longer you take aspirin, the higher your risk.

The data is clear: for healthy seniors without existing heart disease, aspirin offers no meaningful protection. The risks now clearly outweigh the unproven benefits. This marks a major shift in preventive cardiology.

With the rise of dual GLP-1/GIP agonists like tirzepatide, a key question has been: do they offer better heart protection than existing GLP-1 drugs? The answer, according to a recent cardiovascular outcomes trial, is that tirzepatide is noninferior to dulaglutide in reducing major adverse cardiovascular events in patients with type 2 diabetes and established heart disease.

While the study wasn’t powered to show superiority, the results are reassuring. Tirzepatide’s impressive weight loss and glucose-lowering effects don’t come at the cost of cardiovascular safety. In fact, both drugs appear to offer robust protection, continuing the trend of incretin-based therapies being heart-healthy.

For clinicians and patients, this means tirzepatide can be considered a safe alternative—especially for those needing greater metabolic control—without sacrificing cardiovascular outcomes.

Many people stop taking statins due to muscle pain or fatigue. But a clever crossover trial tested whether these symptoms were truly caused by the drug—or by expectation. Participants who had previously quit statins were randomly assigned to take atorvastatin, placebo, or no treatment in a blinded sequence, with daily symptom tracking.

The results? Symptom burden was nearly identical on statin and placebo, and both were higher than during the no-treatment phase. This suggests that the nocebo effect—anticipation of side effects—plays a major role in statin intolerance.

This doesn’t mean side effects aren’t real, but it shows that many people may be avoiding a life-saving drug due to perceived rather than pharmacological effects. Better communication and gradual dosing could help more patients stay on therapy.

Can lifting weights and taking creatine improve more than just muscle? A rigorous 16-week trial says yes. Older adults who did high-load, velocity-intentional resistance training with creatine supplementation saw improvements not only in strength but also in cognitive performance, neuroplasticity, and inflammation markers.

The study compared elastic band training to water-based exercise, with or without creatine. The combo of dry-land resistance training and creatine delivered the best results across physical, cognitive, and biochemical measures. Participants reported better quality of life and reduced oxidative stress.

This is one of the first trials to show that exercise modality and supplementation can jointly influence brain health in aging. For older adults, this combo could be a powerful tool for healthy longevity.

Many with autoimmune hypothyroidism take selenium supplements, hoping to feel better. But a well-designed trial tested this directly: patients on stable levothyroxine therapy were given selenium or placebo for several months. The result? No difference in quality of life, fatigue, or mood between groups.

Despite some earlier promising signals, this high-quality evidence shows that selenium supplementation doesn’t deliver meaningful benefits for most hypothyroid patients already on standard treatment.

That doesn’t mean selenium is useless—it plays a role in thyroid hormone metabolism—but for symptom relief, it’s not a shortcut. Patients should focus on proven therapies and avoid unnecessary supplements.

Semaglutide has shown remarkable benefits for kidney and heart health in people with type 2 diabetes and chronic kidney disease. But does its effect change if patients are already on mineralocorticoid receptor antagonists (MRAs), which also protect the kidneys? A prespecified analysis of the FLOW trial says no—semaglutide’s benefits are independent of MRA use.

Whether patients were on MRAs or not, semaglutide consistently reduced kidney decline and cardiovascular events. This suggests its mechanism complements, rather than overlaps with, existing therapies.

For clinicians, this means semaglutide can be added confidently to complex regimens without worrying about diminished returns.

For three decades, statins have been caught in a storm of controversy—side effects, diabetes risk, and fear of 'chemical overload.' But the latest wave of evidence, including robust trials and meta-analyses, has settled the debate. Statin therapy saves lives by dramatically reducing heart attacks and strokes, even if it slightly nudges blood sugar upward in some.

The small increase in diabetes diagnoses is real but narrow—mostly affecting those already on the edge. And the idea that statins cause widespread muscle pain? Largely a nocebo effect, as blinded trials now show.

It’s time to move past fear and embrace statins for what they are: one of the most effective preventive tools in modern medicine.

Tirzepatide, marketed as Zepbound for weight loss, is gaining attention not just for its efficacy but for off-label use at lower doses. Some users report taking sub-therapeutic doses to manage appetite and metabolism without intense side effects.

While clinical trials focus on full dosing for obesity or diabetes, anecdotal reports suggest low-dose tirzepatide may offer metabolic benefits with better tolerability. However, there’s no robust evidence yet on long-term safety or efficacy at reduced doses.

Still, the interest reflects a growing trend: people seeking precision metabolic control. Until more data exists, caution is advised—but the conversation is shifting toward personalized dosing.

A viral video claims that swapping cashews for another nut can 'clear arteries' and 'drop inflammation.' While nuts in general are heart-healthy, the specific claim lacks evidence. No single nut has been shown to reverse atherosclerosis on its own.

All nuts—almonds, walnuts, pistachios, cashews—offer benefits: healthy fats, fiber, and antioxidants. Some, like walnuts, are higher in omega-3s, which may reduce inflammation. But no clinical trial proves one nut is vastly superior in clearing plaque.

Rather than chasing superfoods, focus on overall dietary patterns. A handful of any unsalted nut daily, as part of a balanced diet, supports heart health.

A recent study on omega-3s and brain health has raised eyebrows—reporting no cognitive benefit or even potential downsides. But context matters. Many omega-3 trials suffer from low doses, short duration, or enrolling people already with advanced decline.

Higher-quality studies show that omega-3s, especially DHA, support brain structure and may slow early cognitive aging. The benefits are subtle and long-term, not dramatic or immediate.

This single 'concerning' result doesn’t overturn the broader evidence. Omega-3s remain important for brain health—especially when started early and taken consistently.

A video claims a 'quiet' heart effect from a vaccine, fueling alarm. But no credible evidence supports widespread cardiac harm from routine vaccines. While rare conditions like myocarditis have been linked to some mRNA vaccines, they are extremely uncommon and typically mild.

In contrast, the diseases these vaccines prevent—like COVID-19—pose far greater heart risks, including myocarditis, arrhythmias, and blood clots.

The real story? Vaccines protect the heart more than they threaten it. Fear-driven narratives ignore this critical risk-benefit balance.

A video claims a 'broken' theory in fat loss—likely referring to outdated ideas like 'calories in, calories out' being too simplistic. While metabolism is complex, involving hormones, gut health, and neurobiology, energy balance still underpins weight change.

Newer models incorporate metabolic adaptation, insulin dynamics, and satiety—but they don’t invalidate physics. Sustainable fat loss requires aligning intake with expenditure, even if the path varies by individual.

The 'broken' theory isn’t energy balance—it’s the oversimplification of how we achieve it.

‘Carb hacking’—timing, type, or cycling carbs for fat loss—has gone viral. Some versions involve eating carbs only post-workout or using resistant starches to blunt glucose spikes.

While smart carb choices can improve insulin sensitivity and satiety, there’s no magic formula. Total intake and food quality matter more than precise timing for most people.

For athletes or those with insulin resistance, strategic carb management may help. But for general weight loss, it’s not a shortcut—just another tool in the toolbox.

Colon cancer rates are rising fast in younger adults—a troubling trend. Potential culprits include ultra-processed diets, sedentary lifestyles, antibiotic overuse, and the obesity epidemic, all of which alter gut microbiota and promote inflammation.

Emerging evidence links dysbiosis—imbalanced gut bacteria—to early carcinogenesis. Diets low in fiber and high in emulsifiers may damage the gut lining and accelerate tumor growth.

The solution? Prioritize whole foods, fiber, and movement. Prevention starts in the gut—and early.